P117. H+-myo-inositol transporter SLC2A13 as a potential marker for cancer stem cells in an oral squamous cell carcinoma

Lee, J.-H.; Lee, D.-G.; Kim, M.-J.; Kim, S.-M.; Li, B.; Kwon, B.

doi:10.1016/j.oraloncology.2011.06.360

Cited by 6 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the fact that both taurine and myo -inositol are elevated in most of the HNSCC cells, it can be hypothesized that these cells experience cell volume perturbation leading to protective and adaptive mechanisms potentially facilitated by the increased expression of the myo -inositol cotransporter (SMIT) and taurine transporter (TauT) (Hoffmann et al, 2009). Increased expression of the myo -inositol transporter SLC2A13 observed in primary cultures of oral squamous cell carcinoma cells (Lee et al, 2011) further supports our observation of elevated myo -inositol levels.…”

Section: Resultssupporting

confidence: 85%

Delineating metabolic signatures of head and neck squamous cell carcinoma: Phospholipase A2, a potential therapeutic target

Tripathi

Kamarajan

Somashekar

et al. 2012

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

A better understanding of molecular pathways involved in malignant transformation of head and neck squamous cell carcinoma (HNSCC) is essential for the development of novel and efficient anti-cancer drugs. To delineate the global metabolism of HNSCC, we report 1H NMR-based metabolic profiling of HNSCC cells from five different patients that were derived from various sites of the upper aerodigestive tract, including the floor of mouth, tongue and larynx. Primary cultures of normal human oral keratinocytes (NHOK) from three different donors were used for comparison. 1H NMR spectra of polar and non-polar extracts of cells were used to identify more than thirty-five metabolites. Principal component analysis performed on the NMR data revealed a clear classification of NHOK and HNSCC cells. HNSCC cells exhibited significantly altered levels of various metabolites that clearly revealed dysregulation in multiple metabolic events, including Warburg effect, oxidative phosphorylation, energy metabolism, TCA cycle anaplerotic flux, glutaminolysis, hexosamine pathway, osmo-regulatory and anti-oxidant mechanism. In addition, significant alterations in the ratios of phosphatidylcholine/lysophosphatidylcholine and phosphocholine/glycerophosphocholine, and elevated arachidonic acid observed in HNSCC cells reveal an altered membrane choline phospholipid metabolism (MCPM). Furthermore, significantly increased activity of phospholipase A2 (PLA2), particularly cytosolic PLA2 (cPLA2) observed in all the HNSCC cells confirm an altered MCPM. In summary, the metabolomic findings presented here can be useful to further elucidate the biological aspects that lead to HNSCC, and also provide a rational basis for monitoring molecular mechanisms in response to chemotherapy. Moreover, cPLA2 may serve as a potential therapeutic target for anti-cancer therapy of HNSCC.

show abstract

Section: Resultssupporting

confidence: 85%

Delineating metabolic signatures of head and neck squamous cell carcinoma: Phospholipase A2, a potential therapeutic target

Tripathi

Kamarajan

Somashekar

et al. 2012

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

show abstract

“…26 SLC2A13 is consistently increased in the cancer stem cells in oral squamous cell carcinoma, it might function as a potential marker for cancer stem cells. 27 So far, there is no study regarding the involvement of SLC2A13 in AML, and for the first time, our study reported increased expression of SLC2A13 was associated with decreased mortality in patients with AML. As SLC2A13 accomplishes tumorigenic effect by influencing the function of Akt, the impact of SLC2A13 expression on the OS of patients with AML is possibly mediated by regulating the function of Akt; however, the detailed mechanism still needs further studies.…”

Section: Discussionmentioning

confidence: 46%

The Solute Carrier Family 2 Genes Are Potential Prognostic Biomarkers in Acute Myeloid Leukemia

Lai

Zhou

et al. 2020

Technol Cancer Res Treat

View full text Add to dashboard Cite

Aims: The solute carrier family 2 (SLC2) genes are comprised of 14 members which are essential for the maintenance of glucose uptake and survival of tumour cells. This study was performed to investigate the associations of SLC2 family gene expression with mortality in acute myeloid leukemia (AML). Methods: Clinical features and SLC2 family gene expression data were obtained from The Cancer Genome Atlas and Gene Expression Omnibus database. The associations between SLC2 family gene expression and clinicopathologic features were analyzed using linear regression model. Kaplan-Meier survival, univariate, multivariate survival analyses and validation analysis were performed to analyze the associations between SLC2 family gene expression and patients’ overall survival. Results: Patient mortality was positively associated with age and cytogenetic risk in AML patients. Kaplan-Meier survival analysis suggested that patients with high SLC2A5 and SLC2A10 expression showed poorer survival than those with low SLC2A5 and SLC2A10 expression. In contrast, patients with high SLC2A13 expression exhibited better prognosis than those with low SLC2A13 expression ( P < 0.05 for all cases, log rank test). Multivariate survival analysis and validation analysis confirmed that high expression of SLC2A5 and SLC2A10 and low expression of SLC2A13 were associated with increased mortality ( P = 0.00, Odd ratio [OR]:4.05, 95% Confidence Interval [CI]: 1.73-10.22; P = 0.00, OR: 3.66, 95% CI: 1.54-9.25; and P = 0.01, OR: 0.26, 95% CI: 0.09-0.68, respectively). Conclusion: SLC family gene expression, such as SLC2A5, SLC2A10 and SLC2A13, was significantly associated with prognosis of AML patients, their expression levels might become useful prognostic biomarkers in AML.

show abstract

“…They have also proven it to be superior to CRC biomarker and CEA and validated their results by immunohistochemistry [95]. Lee and coworkers have established H + -myo-inositol transporter SLC2A13 as a potential biomarker for cancer stem cell (CSC) in oral squamous cell carcinoma (OSCC) [111]. Head and neck carcinoma is one of the poorly understood cancer and there is a need of biomarkers for its diagnosis and prognosis at early stages.…”

Section: Advantages Of Tissue Culture In Biomarker Discovery and Diagmentioning

confidence: 97%

High Throughput Sequencing and Proteomics to Identify Immunogenic Proteins of a New Pathogen: The Dirty Genome Approach

2014

Omics in Clinical Practice

View full text Add to dashboard Cite

Accurate diagnosis and proper monitoring of cancer patients remain a key obstacle for successful cancer treatment and prevention. Therein comes the need for biomarker discovery, which is crucial to the current oncological and other clinical practices having the potential to impact the diagnosis and prognosis. In fact, most of the biomarkers have been discovered utilizing the proteomicsbased approaches. Although high-throughput mass spectrometry-based proteomic approaches like SILAC, 2D-DIGE, and iTRAQ are filling up the pitfalls of the conventional techniques, still serum proteomics importunately poses hurdle in overcoming a wide range of protein concentrations, and also the availability of patient tissue samples is a limitation for the biomarker discovery. Thus, researchers have looked for alternatives, and profiling of candidate biomarkers through tissue culture of tumor cell lines comes up as a promising option. It is a rich source of tumor cell-derived proteins, thereby, representing a wide array of potential biomarkers. Interestingly, most of the clinical biomarkers in use today (CA 125, CA 15.3, CA 19.9, and PSA) were discovered through tissue culture-based system and tissue extracts. This paper tries to emphasize the tissue culture-based discovery of candidate biomarkers through various mass spectrometry-based proteomic approaches.

show abstract

P117. H+-myo-inositol transporter SLC2A13 as a potential marker for cancer stem cells in an oral squamous cell carcinoma

Cited by 6 publications

References 0 publications

Delineating metabolic signatures of head and neck squamous cell carcinoma: Phospholipase A2, a potential therapeutic target

Delineating metabolic signatures of head and neck squamous cell carcinoma: Phospholipase A2, a potential therapeutic target

The Solute Carrier Family 2 Genes Are Potential Prognostic Biomarkers in Acute Myeloid Leukemia

High Throughput Sequencing and Proteomics to Identify Immunogenic Proteins of a New Pathogen: The Dirty Genome Approach

Contact Info

Product

Resources

About